welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!
status unknown

Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI

key information

study id #: NCT01307527

condition: Brittle Cornea Syndrome, Ehlers-Danlos Syndrome Type 6

status: unknown


Brittle Cornea Syndrome and Ehlers-Danlos Syndrome (EDS) type VI are rare collagen-connective tissue disorders that predispose affected individuals to the development of perforated corneas from the mildest of eye trauma or even spontaneously. Clinical studies evaluating riboflavin-corneal crosslinking have found that it dramatically increases corneal rigidity. Given the success and safety of riboflavin crosslinking, the investigators believe that it can increase the corneal stability in patients affected these disseases, preventing perforation. It is furthermore possible, that riboflavin crosslinking will allow corneal transplants to successfully be performed on blind eyes that have already perforated and opacified. The purpose of the study is to determine whether corneal crosslinking can be safely performed on individuals with Brittle Cornea Syndrome or Ehlers-Danlos Syndrome type VI.

intervention: Drug: Riboflavin
0.1%, applied every 5 minutes for 60 minutes
Device: Kera-X
3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes